Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ: SRPT )

59.49 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 926
Open 59.49
Bid (Size) 58.73 (1)
Ask (Size) 61.40 (1)
Prev. Close 59.49
Today's Range 59.49 - 59.49
52wk Range 48.01 - 173.25
Shares Outstanding 93,148,652
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
From Sarepta Therapeutics, Inc.
Via Business Wire
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire

Performance

YTD
-52.06%
-52.06%
1 Month
-22.06%
-22.06%
3 Month
-48.76%
-48.76%
6 Month
-54.20%
-54.20%
1 Year
-49.21%
-49.21%

More News

Read More
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
Netflix To Rally More Than 55%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
From Sarepta Therapeutics, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
NASDAQ: SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via NewMediaWire
Topics Fraud
Exposures Legal
NASDAQ: SRPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors with Significant Losses to Contact the Firm
Via TheNewswire.com
Topics Fraud
Exposures Legal
Can Solid Biosciences Challenge Sarepta in the DMD Market?
Via MarketBeat
3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
Via StockStory
Topics Supply Chain
Exposures Supply Chain
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
From Pomerantz LLP
Via GlobeNewswire
4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
Via The Motley Fool
Sarepta Therapeutics Temporarily Halts Three Clinical Studies Of Elevidys: Retail Is Dull While Stock Drops
Via Stocktwits
Topics Government
Exposures Political
Sarepta Therapeutics Provides Update on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Via Benzinga
Apple To $250? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
Via Investor's Business Daily
Topics Death
Exposures Death
Deep Dive Into Sarepta Therapeutics Stock: Analyst Perspectives (18 Ratings)
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.